Received Aug 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
patient who wanted to finish Twinrix schedule in a month, however Twinrix first dose was on 7/11/2025 and Twinrix second dose was on 2nd 7/23/2025.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received HAB (Twinrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 23-JUL-2025, the patient received the 2nd dose of Twinrix. On 23-JUL-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: patient who wanted to finish Twinrix schedule in a month, however Twinrix first dose was on 7/11/2025 and Twinrix second dose was on 2nd 7/23/2025.). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-JUL-2025 The pharmacist had an adult female patient who wanted to finish Twinrix schedule in a month, however Twinrix first dose was on 11th July 2025 and Twinrix second dose was on 2nd 23rd July 2025 which led to lengthening of vaccination schedule. The vaccine administration facility was the same as primary reporter.